Olga Sagalova, MD, PhD

South Ural State Medical University, Chelyabinsk, Russian Federation
Chelyabinsk, Moskva, Russia

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 83 - Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a

  Thursday, October 17, 2024
  10:45 AM – 11:00 AM US PT

• 521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

  Saturday, October 19, 2024
  12:20 PM – 12:25 PM US PT